 |
|
Milestone for cannabinoid MS study
July 22, 2008Study to investigate link between cannabis compound and slowing of multiple sclerosis
The CUPID (Cannabinoid Use in Progressive Inflammatory brain Disease) study at the Peninsula Medical School in Plymouth has reached an important milestone with the news that the full cohort of 493 people with multiple sclerosis (MS) has been recruited to the study.
CUPID is a clinical trial which will evaluate whether tetrahydrocannabinol (THC), one of many compounds found in the in the cannabis plant (and the main active ingredient) is able to slow the progression of MS.
This is an important study for people with MS because current treatments either target the immune system in the early stages of MS, or are aimed at easing specific symptoms such as muscle spasms or bladder problems. At present there is no treatment which slows progression of the disease.
The CUPID trial follows an earlier study - Cannabinoids and Multiple Sclerosis (CAMS) - which suggested a link between THC and the slowing of MS. The CAMS trial saw participants take THC for a year - the CUPID trial will last for longer and aims to assess the effect of THC on progressive MS.
It has taken two years to recruit the 493 participants who will each take part in the trial for three years, and in some cases three and a half years. After data cleaning and analysis the results should be available by spring/early summer 2012.
Professor John Zajicek from the Peninsula Medical School, who heads the team carrying out the CUPID study, said: "We are delighted to have achieved the correct number of patient participants for this trial. Patients have been recruited from 27 sites across the UK. If we are able to prove beyond reasonable doubt the link between THC and the slowing down of progressive MS, we will be able to develop an effective therapy for the many thousands of MS sufferers around the world."
The CUPID trial is funded by the Medical Research Council, the Multiple Sclerosis Society and the Multiple Sclerosis Trust.
Chris Jones, chief executive of the MS Trust, commented: "The MS Trust is delighted to be supporting this study on behalf of people with MS. The ability to halt progression in MS is what we dream of - the Holy Grail for those whose condition deteriorates year on year. This study should give us the definitive answer as to whether cannabinoids will prove to be such an agent."
Dr Laura Bell, research communications officer for the MS Society, said: "People affected by MS are keen to know whether there's any truth in the suggestion that elements of the cannabis plant can help ease the symptoms and slow down progression of the condition.
"The MS Society is supportive of safe clinical trials investigating the medicinal properties of cannabis and it's great news that this trial is going ahead. We look forward to the results of this exciting study."
The Peninsula College of Medicine and Dentistry
This is an important study for people with MS because current treatments either target the immune system in the early stages of MS, or are aimed at easing specific symptoms such as muscle spasms or bladder problems. At present there is no treatment which slows progression of the disease.
The CUPID trial follows an earlier study - Cannabinoids and Multiple Sclerosis (CAMS) - which suggested a link between THC and the slowing of MS. The CAMS trial saw participants take THC for a year - the CUPID trial will last for longer and aims to assess the effect of THC on progressive MS.
It has taken two years to recruit the 493 participants who will each take part in the trial for three years, and in some cases three and a half years. After data cleaning and analysis the results should be available by spring/early summer 2012.
Professor John Zajicek from the Peninsula Medical School, who heads the team carrying out the CUPID study, said: "We are delighted to have achieved the correct number of patient participants for this trial. Patients have been recruited from 27 sites across the UK. If we are able to prove beyond reasonable doubt the link between THC and the slowing down of progressive MS, we will be able to develop an effective therapy for the many thousands of MS sufferers around the world."
The CUPID trial is funded by the Medical Research Council, the Multiple Sclerosis Society and the Multiple Sclerosis Trust.
Chris Jones, chief executive of the MS Trust, commented: "The MS Trust is delighted to be supporting this study on behalf of people with MS. The ability to halt progression in MS is what we dream of - the Holy Grail for those whose condition deteriorates year on year. This study should give us the definitive answer as to whether cannabinoids will prove to be such an agent."
Dr Laura Bell, research communications officer for the MS Society, said: "People affected by MS are keen to know whether there's any truth in the suggestion that elements of the cannabis plant can help ease the symptoms and slow down progression of the condition.
"The MS Society is supportive of safe clinical trials investigating the medicinal properties of cannabis and it's great news that this trial is going ahead. We look forward to the results of this exciting study."
The Peninsula College of Medicine and Dentistry
Multiple Sclerosis News and Current Multiple Sclerosis Events RSSTrapping white blood cells proves novel strategy against chronic viral infections
Seeing disease-fighting white blood cells vanish from the blood usually signals a weakened immune system. But preventing white blood cells' circulation by trapping them in the lymph nodes can help mice get rid of a chronic viral infection, researchers at Yerkes National Primate Research Center and the Emory Vaccine Center have found.
Trapping white blood cells proves novel strategy against chronic viral infections
Seeing disease-fighting white blood cells vanish from the blood usually signals a weakened immune system. But preventing white blood cells' circulation by trapping them in the lymph nodes can help mice get rid of a chronic viral infection, researchers at Yerkes National Primate Research Center and the Emory Vaccine Center have found.
Protein complementarity may offer new insights into autoimmune diseases
The discovery of "complementary" antibodies against plasminogen in patients with blood vessel inflammation caused by anti-neutrophil cytoplasmic autoantibodies (ANCAs) may lead to new approaches to research, testing, and treatment of ANCA vasculitis and other autoimmune diseases, suggests a paper in the December Journal of the American Society of Nephrology (JASN).
UNC study: shape, not just size, impacts effectiveness of emerging nanomedicine therapies
In the budding field of nanotechnology, scientists already know that size does matter. But now, researchers at the University of North Carolina at Chapel Hill have shown that shape matters even more - a finding that could lead to new and more effective methods for treating cancer and other diseases, from diabetes and multiple sclerosis to arthritis and obesity.
Multiple Sclerosis: new MRI contrast medium enables early diagnosis in animal model
In an animal model of multiple sclerosis (MS), neuroradiologists and neurologists of the University hospitals of Heidelberg and Würzburg have been able to visualize inflammatory tissue damage, most of which had remained unrecognized up to now, with the aid of a new contrast medium, Gadofluorine M, in magnetic resonance imaging.
New Guidelines for Treating Rheumatoid Arthritis
Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham (UAB).
Statins have unexpected effect on pool of powerful brain cells
Cholesterol-lowering drugs known as statins have a profound effect on an elite group of cells important to brain health as we age, scientists at the University of Rochester Medical Center have found. The new findings shed light on a long-debated potential role for statins in the area of dementia.
Best treatment for MS may depend on disease subtype
Animal studies by University of Michigan scientists suggest that people who experience the same clinical signs of multiple sclerosis (MS) may have different forms of the disease that require different kinds of treatment.
Medicines derived from cannabis: a review of adverse events
Researchers at the McGill University Health Centre (MUHC), McGill University and the University of British Columbia (UBC) determined that medical use of cannabinoids do not cause an increase in serious adverse events, but are associated with an increase in some non-serious adverse events.
Developing unique brain maps to assist surgery and research
Researchers from the Howard Florey Institute in Melbourne are developing new technology to create individualised brain maps that will revolutionise diagnosis of disease and enhance the accuracy of brain surgery.
More Multiple Sclerosis News Articles
 | Living Well: 21 Days to Transform Your Life, Supercharge Your Health, andFeel Spectacular by Montel Williams, William Doyle In the fight for health and happiness, New York Times bestselling author Montel Williams shares his battle plan for better living. In his inspiring autobiography Climbing Higher, Montel Williams told the story of his lifelong struggle for respect and success-and his ongoing struggle with multiple sclerosis. In Body Change: The 21-Day Fitness Program for Changing Your Body...and Changing Your... |
 | The MS Recovery Diet by Ann Sawyer, Judith Bachrach More than half a million people live with multiple sclerosis, yet conventional medicine still has little to offer patients. There is no known cure-and even recent breakthroughs in drug therapy do not work to control many of the symptoms or promise any degree of recovery. But there is an alternative to drugs that can stop and reverse the ravaging symptoms of MS-the MS Recovery Diet. As this book... |
 | Yoga and Multiple Sclerosis: A Journey to Health and Healing by Loren Martin Fishman, B. Phil, Eric Small Yoga for people with multiple sclerosis? Absolutely! Studies show that after six months of practicing yoga, fatigue and other symptoms are significantly reduced. Yoga and Multiple Sclerosis: A Journey to Health and Healing is a comprehensive and user-friendly guide to applying the principles of yoga to managing your MS. Yoga and Multiple Sclerosis contains information for people experiencing... |
 | The Multiple Sclerosis Diet Book by Roy Laver Swank, Barbara Brewer Dugan Hundreds of new recipes for dishes that taste terrific but stick to the diet rules so important for controlling M.S.--now completely revised to conform to the latest medical... |
 | Healing Multiple Sclerosis: Diet, Detox & Nutritional Makeover for Total Recovery by Ann Boroch Multiple Sclerosis can now be healed and this book shows you how. Though MS is widely believed to be incurable, Boroch's breakthrough treatment protocol can dramatically restore patients to health. This landmark book describes her own tumultuous journey with MS: • Her quest for a cure • Case histories of those who have triumphed over MS • The real causes of MS • How to... |
 | Exercises for Multiple Sclerosis: A Safe and Effective Program to Fight Fatigue, Build Strength, and Improve Balance (Exercises for) by Brad Hamler Fight the impact of MS through fitness with specially designed exercises.In the U.S. alone, approximately 400,000 people have multiple sclerosis (MS). MS is an autoimmune disease that affects the central nervous system. There are a variety of symptoms of MS and it affects people in different ways, but there is no cure.Fitness can help strengthen debilitated bodies, and make living with the... |
 | Complementary and Alternative Medicine and Multiple Sclerosis by Allen C. Bowling The first edition of this authoritative book quickly became the single source for accurate and unbiased information on complementary and alternative medicine approaches for the management of MS symptoms. The second edition, completely updated throughout, reflects advances in the field since the book’s initial publication in 2001. Therapies are organized alphabetically so that readers can... |
 | The First Year: Multiple Sclerosis: An Essential Guide for the Newly Diagnosed (The First Year) by Margaret Blackstone One of the most widely recommended guides to living with multiple sclerosis, now completely revised and updated, including the latest research, the most recent information on treatments (including the news on TysabriŽ), and new tips for managing MS. Multiple sclerosis is as much a mystery as it is a disease, but this chronic and often disabling condition of the central nervous system affects over... |
 | Mental Sharpening Stones: Manage the Cognitive Challenges of Multiple Sclerosis by Jeffrey N. Gingold Mental Sharpening Stones: Manage the Cognitive Challenges of Multiple Sclerosis provides real-life techniques garnered from MS patients and their medical providers, sharing their practical methods for pushing back against the disruptive and potentially disabling cognitive symptoms that affect MS patients. The book offers strategies that will assist those living with MS to retain their... |
 | MS and Your Feelings: Handling the Ups and Downs of Multiple Sclerosis by Allison Shadday MS and Your Feelings is the first book to specifically address the emotional pain caused by the unpredictable, disabling chronic inflammatory condition multiple sclerosis. Psychotherapist and MS patient Allison Shadday offers readers effective strategies for dealing with the psychological trauma of this disease. Shadday shares real-life MS success stories and gives insightful professional advice... |
| © 2008 BrightSurf.com |